BAY 0 9867 Cipro Pediatric Use Study (QUIP)

Inclusion Criteria: * Patient is \>/= 2 months of age through 16 years of age * A parent/caregiver must sign an informed consent * Patient must provide assent, as appropriate based on local institutional review board guidelines Exclusion Criteria: * Patients presenting with the following conditions: * exacerbations of cystic fibrosis (CF) * meningitis * Brain abscess * bacterial endocarditis, * Bone and joint infections * having any of the following conditions but lacking a personal history may be admitted to the trial: * Arthritis * Juvenile rheumatoid arthritis (JRA) * Rheumatoid arthritis (RA) * Systemic lupus erythematosis (SLE) * History of rheumatic fever * Psoriasis * Inflammatory bowel disease * Osteoarthritis (OA) * Known underlying rheumatological disease, joint problems known to be associated with arthropathy. * Patients with any pre-treatment baseline musculoskeletal exam abnormalities * Known risk of experiencing seizures, a history of any convulsive disorders * Requiring any concomitant therapeutic course of systemic antibacterial agent * Participation in any industry-sponsored clinical drug development study within one month prior to this study * Known significant liver impairment (ALAT/ASAT and/or baseline bilirubin \> 3 times upper limit of normal) * Known significant renal insufficiency (calculated creatinine clearance of \< 30 ml/min/1.73 m²) * Are pregnant or lactating, or are sexually active and using unreliable contraception.